Halloween Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:NVO
Novo-Nordisk (NVO)
37.88
-0.38 (0.99%)
as of Oct 8, 2026, 6:40:21 pm Market Open.
267 watching
Financials 
Technical Analysis 0
BUY
BUY
Does not own any stock in company, Has had impressive sales record with organic growth. Pressure on diabetes pricing in the USA. Expecting new products coming onto market to benefit the company. Large portion if US(40%) living with obesity. Expensive at current share price.
biotechnologypharmaceutical
BUY
Likes company and has owned shares for a long time.
#1 company in European diabetic market.
Share prices are a little over priced.
Will continue holding shares for the long term.
Darren SissonsOwned
biotechnologypharmaceutical
WEAK BUY
NVO vs. LLY Focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Feb 10/21, Up 46%) Believes company is leading insulin producer for diabetics.
Revenues outside USA are increasing.
Above average financial results from previous quarter was rewarded by market.
Rising diabetes levels in society will be good for company.
Company has very little debt and is looking at other products.
David DriscollOwned
biotechnologypharmaceutical
COMMENT
He was negative on this 5 years ago but now likes it and owns some for the long term. Insulin prices have normalized and it has a good weight loss drug. When asked to compare to Lilly he prefers NVO although Lilly is good too. The only concern is that this is a defensive growth stock and some might sell to buy cyclicals.
David FingoldOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Feb 10/21, Up 49%) Leading company for making insulin. The FDA approved their 2.5mg dose of weight-loss drug, which helped share prices. They are first to market with it. The expectations for earnings were moved higher. Getting more international sales in the long term. Stock is starting to get noticed by fund managers internationally.
David DriscollOwned
biotechnologypharmaceutical
HOLD
Largest producer of insulin in the world. Diabetes is one of the fastest-growing diseases. Will continue to do well.
Paul Harris, CFAOwned
biotechnologypharmaceutical
TOP PICK
A long time favourite. Recent news was FDA approval of a diabetes drug that can also be used for weight-loss. (Analysts’ price target is $76.50)
David DriscollOwned
biotechnologypharmaceutical
TOP PICK
Take a pill once a week instead of injecting. Big implications moving forward. International sales have gone beyond what US sales were. Good entry point for the next 5-10 years. May get more diversified over time. No debt outstanding. Yield is 1.45% (Analysts’ price target is $75.73)
David DriscollOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Good entry point, as it's pulled back from its high. Obesity causes Type 2 diabetes, the fastest-growing disease in NA. Globally, it's also becoming a problem. There's competition, but the potential is massive. Owning here makes sense.